Semaglutide in Nonalcoholic Fatty Liver Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

Also called NCT05813249

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 180 participants (enrolled count) (from the registry)
Sponsor
Zagazig University (from the registry)
Registry
  • NCT NCT05813249
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05813249. Non-randomized; no masking; primary purpose treatment. Start 2023-02-15 (actual); primary completion 2024-02-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Semaglutide in Nonalcoholic Fatty Liver Disease
Condition
Non-alcoholic Fatty Liver Disease
Intervention (Drug)
Rybelsus Oral Product
Intervention (Drug)
Ozempic Injectable Product
Intervention (Drug)
Tocopherol and/or Actos
Lead sponsor
Zagazig University (class: other government)

Record details

Record id
cardio:ct-nct05813249
Content hash
2e78caf122c05b9b01de56b7369b720bad0dad8ba209687572c6aa8bf00d4f00